This five year K08 Career Development Award proposal for Dr. Christopher Barbieri describes a career development program designed to culminate in a career as an independent investigator in Urologic Oncology. Dr. Barbieri is an urologist at Weill Cornell Medical College, committed to a career as a surgeon-scientist focused on the molecular characterization of prostate cancer. This Career Development Award will allow Dr. Barbieri to become an expert in the molecular characterization of prostate cancer, and translate this research into the clinical care of prostate cancer patients. Dr. Barbieri will be mentored by Dr. Mark Rubin, a leader in the field of prostate cancer genomics and molecular classification of the disease. Dr. Rubin is Vice Chair for Experimental Pathology and Director of the Institute for Precision Medicine at Weill Cornell Medical College, and has overseen the career development of numerous young investigators. Research training will be enhanced by an outstanding team of collaborators to allow development of skills in genomics, mouse modeling, and computational biology. Finally, an advisory committee composed of well-recognized individuals serving roles as clinicians, scientists, and institutional leaders will further guide career development. The research proposal focuses on genomic rearrangements, which play a critical role in the pathogenesis of prostate cancer. Recently described recurrent mutations in SPOP define a novel molecular subclass of prostate cancer characterized by striking increases in total genomic rearrangements compared to other subtypes. The central hypothesis of this proposal is that SPOP mutant prostate cancers have distinct management of DNA break formation and repair, leading to effects on genomic rearrangements, altered sensitivity to therapeutic agents, and potentially effects on patient prognosis.
Specific Aims i nclude: 1) To elucidate the role of SPOP mutation in the formation and repair of DNA breaks in prostate cells. 2) To determine the effect of SPOP mutation on the sensitivity of prostate cancer cells to therapeutic agents affecting DNA damage and repair. 3) To define the association of SPOP mutations with patient outcomes and deregulation of DNA damage pathways in a large, well annotated cohort of radical prostatectomy specimens. Together, these studies will define the role of SPOP mutations in genomic instability, nominate potential inhibitors of SPOP mutant prostate cancer, and define the effect of SPOP mutation on the outcomes of patients with prostate cancer.

Public Health Relevance

Prostate cancer, a common and often lethal disease, is driven by genomic instability resulting in the gain, loss, or repositioning of large segments of DNA. Mutations in the SPOP gene define a distinct class of prostate cancer, with significantly increased numbers of total genomic rearrangements. This project will dissect the mechanisms by which SPOP mutations predispose to genomic rearrangements, investigating the function of the SPOP protein in DNA damage and repair, searching for therapies that can exploit the specific deficits in SPOP mutant cancers, and exploring the impact of SPOP mutations on patients with prostate cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Perkins, Susan N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Weill Medical College of Cornell University
Schools of Medicine
New York
United States
Zip Code
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386
Mateo, Joaquin; Boysen, Gunther; Barbieri, Christopher E et al. (2017) DNA Repair in Prostate Cancer: Biology and Clinical Implications. Eur Urol 71:417-425
Barbieri, Christopher E; Chinnaiyan, Arul M; Lerner, Seth P et al. (2017) The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol 71:237-246
Dutta, Aditya; Panja, Sukanya; Virk, Renu K et al. (2017) Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5?-reductase Inhibition. Eur Urol 72:499-506
Lee, D; Fontugne, J; Gumpeni, N et al. (2017) Molecular alterations in prostate cancer and association with MRI features. Prostate Cancer Prostatic Dis 20:430-435
Blattner, Mirjam; Liu, Deli; Robinson, Brian D et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 31:436-451
Kaffenberger, Samuel D; Barbieri, Christopher E (2016) Molecular subtyping of prostate cancer. Curr Opin Urol 26:213-8
Shoag, Jonathan; Mittal, Sameer; Halpern, Joshua A et al. (2016) Lethal Prostate Cancer in the PLCO Cancer Screening Trial. Eur Urol 70:2-5
Boysen, Gunther; Barbieri, Christopher E; Prandi, Davide et al. (2015) SPOP mutation leads to genomic instability in prostate cancer. Elife 4:
Barbieri, Christopher E; Rubin, Mark A (2015) Genomic rearrangements in prostate cancer. Curr Opin Urol 25:71-6